COVID-19 inactivated booster vaccines elicit strong protection against SARS-CoV-2 wild-type and Omicron variant in patients with breast cancer
Breast cancer patients boosted with a third dose of inactivated vaccines demonstrated the potent neutralization of SARS-CoV-2 and the Omicron variant compared to receiving one or two doses. Vaccination-mediated NAb induction was affected by age, time > 6 months after vaccination, vaccine type, and cancer-targeted treatment. Therefore, the study results indicated an urgent need for caution and additional strategies to protect these patients.
Authors
- Yongzhe Li (ORCID: https://orcid.org/0000-0002-8267-0985)
- Linrong Li (ORCID: https://orcid.org/0000-0003-4106-6463)
- Haoting Zhan (ORCID: https://orcid.org/0000-0001-5934-9141)
- Xiaomeng Li (ORCID: https://orcid.org/0000-0003-3966-2864)
- Yongmei Liu (ORCID: https://orcid.org/0000-0002-6562-1858)
- Yali Xu (ORCID: https://orcid.org/0009-0007-7772-3548)
- Qiang Sun (ORCID: https://orcid.org/0009-0001-9345-302X)
- Haolong Li (ORCID: https://orcid.org/0000-0002-7865-3306)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University (CN)
- Peking Union Medical College Hospital (CN)
- Peking University People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-04-01
- DOI
- https://doi.org/10.3389/fmed.2025.1516492
- Primary Topic
- COVID-19 and healthcare impacts
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Chinese Academy of Medical Sciences
- Peking University
- Peking University People's Hospital